{"filing":{"accession_number":"0001640334-26-001437","cik":"0001348362","ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-28","primary_document":"lxrp_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001437/lxrp_8k.htm"},"events":[{"id":30836,"run_id":28276,"accession_number":"0001640334-26-001437","anchor_item_number":"8.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Lexaria received an Australian R\u0026D tax credit of AUD$3.67M (USD$2.6M) from the Australian Tax Office for research and development costs associated with its clinical study GLP-1-H24-4. This is a material financial event—a non-operating credit that increases cash available for operations—but does not fit the specific financial categories (debt issuance, dividend distribution, impairment, restatement, etc.). The credit is clearly financial in nature and material to a reasonable investor assessing the company's liquidity and funding for R\u0026D activities.","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33558,"accession_number":"0001640334-26-001437","item_number":"8.01","item_title":"Other Events","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Lexaria received an Australian R\u0026D tax credit of AUD$3.67M (USD$2.6M) from the Australian Tax Office for research and development costs associated with its clinical study GLP-1-H24-4. This is a material financial event—a non-operating credit that increases cash available for operations—but does not fit the specific financial categories (debt issuance, dividend distribution, impairment, restatement, etc.). The credit is clearly financial in nature and material to a reasonable investor assessing the company's liquidity and funding for R\u0026D activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:17:45.302830+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33558,"accession_number":"0001640334-26-001437","item_number":"8.01","item_title":"Other Events","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Lexaria received an Australian R\u0026D tax credit of AUD$3.67M (USD$2.6M) from the Australian Tax Office for research and development costs associated with its clinical study GLP-1-H24-4. This is a material financial event—a non-operating credit that increases cash available for operations—but does not fit the specific financial categories (debt issuance, dividend distribution, impairment, restatement, etc.). The credit is clearly financial in nature and material to a reasonable investor assessing the company's liquidity and funding for R\u0026D activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:17:45.302830+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-09-01"}]}